Charles de Rohan
Charles de Rohan, CEO of the Binding Site, has worked in the diagnostic industry for over 17 years. The Binding Site is a Birmingham-based manufacturer of immunodiagnostic products, and has a global turnover of around £43 million. It was recognized by its third Queen’s Award for Enterprise in 2011.
Charles was previously CEO of London-quoted Genetix Group, a highly profitable and fast-growing cell imaging and analysis company with revenues exceeding $50m. By moving Genetix’s strategic focus from products to customers, he broadened its offering through the introduction of new tools and processes and the identification of complementary acquisitions. In 2009 he successfully negotiated the takeover of Genetix by Danaher Corporation, where it forms part of Leica Microsystems.
Prior to joining Genetix, Charles spent 15 years at Abbott Laboratories' Diagnostic Division, where he held a number of senior commercial management positions in Europe and Asia Pacific. From November 2003 he was Divisional Vice President in Commercial Operations, managing various European operations. In December 2006 he established a new role as Divisional Vice President, Scientific Leadership and Global Accounts EMEA, where he was responsible for pursuing potential new business models for the core laboratory business as well as developing and executing a strategy to differentiate the company’s offering through its science.
Charles began his career in 1984 at Ernst and Young, where he trained as a chartered accountant, working in a number of positions including forensic accounting, before moving into the management consultancy side of the business.
